Biotechnology and its Applications — NEET Notes

Where biotechnology touches our lives

Biotechnology — in the NCERT's own framing — is the industrial-scale production of biopharmaceuticals and biologicals using genetically modified microbes, fungi, plants, and animals. Its applications stretch across therapeutics, diagnostics, genetically modified crops, processed food, bioremediation, waste treatment, and energy. Three research thrusts hold the discipline together: providing the best catalyst (usually an improved microbe or pure enzyme), creating the optimal conditions for that catalyst to work, and developing the downstream processing needed to purify the final protein or organic compound. Everything that follows in this chapter — Bt cotton, recombinant insulin, gene therapy, ELISA — is an expression of those three principles.

Genetic engineering moved biology from observation to invention — we no longer merely describe life, we design it.

The central pivot of modern biotechnology

The applications group naturally into four NEET-tested arenas: agriculture, medicine, transgenic animals, and ethics. Before the deep dive, anchor the headline facts of each in a single grid — these are the bedrock numbers and dates examiners return to.

Biotechnological applications in agriculture

Three roads to higher food production stretch before modern agriculture: agrochemical-based farming, organic farming, and genetic-engineering-based farming. The Green Revolution tripled food supply but plateaued: better-managed agrochemicals and improved varieties carried us only so far. Conventional breeding could not keep pace with population growth. Tissue culture filled some of the gap — totipotent explants regenerated in sterile nutrient media yielding thousands of somaclones through micropropagation, and meristem culture rescuing virus-free banana, sugarcane, and potato from infected stock. Somatic hybridisation of naked protoplasts even produced curiosities such as the pomato. Yet none of these methods could simply install a new trait at will. Genetic engineering could — and the resulting organisms are called Genetically Modified Organisms (GMOs).

GM plants have delivered, in NCERT's enumeration: tolerance to abiotic stresses (cold, drought, salt, heat); reduced reliance on chemical pesticides through pest-resistant crops; reduced post-harvest losses; more efficient mineral use (slowing soil-fertility exhaustion); and enhanced nutritional value — golden rice, vitamin-A-enriched, being the textbook example NEET 2019 asked. Crops have also been tailored to deliver alternative industrial resources — starches, fuels, pharmaceuticals.

Bt cotton & pest-resistant plants

The flagship achievement of biotech agriculture is the production of pest-resistant plants that need far less insecticide. The toxin doing the work is Bt toxin, produced by the soil bacterium Bacillus thuringiensis — "Bt" for short. Bt strains synthesise crystalline protein bodies during a particular growth phase, and these crystals contain a toxic insecticidal protein. Specific strains target specific insect orders: lepidopterans (tobacco budworm, armyworm), coleopterans (beetles), and dipterans (flies, mosquitoes). The toxin gene was isolated from the bacterium and inserted into cotton (and corn, rice, tomato, potato, soybean) — creating, in effect, a built-in bio-pesticide. The Bt cotton variant approved in India for commercial release carries the cryIAc and cryIIAb genes, which together control the cotton bollworms responsible for the worst damage in the crop. A related gene, cryIAb, targets the corn borer — the toxin choice is dictated by the pest because most Cry proteins are tightly insect-group specific.

The most testable detail in the entire chapter is why the toxin does not kill the bacterium that makes it, and what changes when an insect ingests it. The answer is pH-driven activation:

RNA interference — silencing the parasite

Bt cotton attacks lepidopteran larvae with a toxic protein; the next example does something more elegant — it makes a plant invisible to a parasite by silencing the parasite's own genes. The pest in question is Meloidogyne incognita, a root-knot nematode that infects tobacco roots and devastates yield. The strategy is RNA interference (RNAi), a defensive mechanism present in all eukaryotic organisms in which a double-stranded RNA molecule binds to and silences a specific mRNA. The dsRNA can come from RNA-genome viruses or from mobile genetic elements (transposons) that replicate via an RNA intermediate — and now, in transgenic plants, from designed constructs.

Using Agrobacterium vectors, scientists introduced nematode-specific genes into tobacco. The design was deliberate: the introduced DNA produced both sense and antisense RNA in the host root cells. Being complementary, these strands paired to form double-stranded RNA, which triggered the RNAi pathway. The targeted mRNA, copied from a nematode gene essential to the parasite, was silenced. The consequence: the nematode could not survive in a transgenic host expressing the interfering RNA — and the plant protected itself. Control plants had heavily galled, malformed roots after deliberate infection. Transgenic plants, five days after the same challenge, were clean.

Biotechnological applications in medicine

Recombinant DNA technology has rewritten healthcare by enabling mass production of safe, effective therapeutic drugs. Two advantages run through every example. First, because the recombinant therapeutic is identical to the human protein it replaces, it does not provoke unwanted immune responses the way animal-derived equivalents do. Second, the supply is uncoupled from animal sources — a fermenter of E. coli can yield as much insulin as the global diabetic population needs, indefinitely. Roughly 30 recombinant therapeutics have been approved for human use worldwide; 12 of these are marketed in India at present. Three NEET pillars sit inside this branch: recombinant insulin, gene therapy, and molecular diagnosis.

Genetically engineered insulin — Humulin

Adult-onset diabetes is managed by regular insulin injections. Before recombinant DNA, the only source was the pancreas of slaughtered cattle and pigs — a supply chain that was expensive, finite, and occasionally allergenic, because animal insulin is not identical to human insulin and could provoke immune reactions in some patients. The solution had been imagined for years: engineer a bacterium that produces human insulin. The technical hurdle was assembly.

Insulin is two short polypeptides — chain A and chain B — held together by disulphide bridges. In the human pancreas it is first synthesised as a pro-hormone containing an extra stretch called the C-peptide, which is cleaved off during maturation. Mature insulin has no C-peptide. To copy the natural maturation pathway inside a bacterium would have required precise enzymatic cleavage of pro-insulin — a serious problem. In 1983, the American company Eli Lilly chose a different route. They prepared two DNA sequences corresponding to chains A and B of human insulin separately, introduced them into plasmids of E. coli, and harvested the two chains independently. The chains were then extracted and combined by creating disulphide bonds between them — yielding mature human insulin, marketed as Humulin. The C-peptide problem was bypassed simply by never producing pro-insulin in the first place.

The take-home for NEET is the difference between natural and engineered routes: pro-insulin (natural) contains the C-peptide and matures by losing it; rDNA insulin (Humulin) never had a C-peptide because A and B were synthesised separately and joined directly.

Gene therapy — fixing the defect at the source

Where recombinant therapy supplies a missing protein from outside, gene therapy attempts something more ambitious: insert a functional copy of the gene itself into the patient's cells so the body produces the protein on its own. Formally, gene therapy is a collection of methods that allow correction of a gene defect diagnosed in a child or embryo. A normal gene is delivered into the individual (or embryo) to take over the function of and compensate for the non-functional gene.

The first clinical gene therapy was given in 1990 to a four-year-old girl with adenosine deaminase (ADA) deficiency. ADA is an enzyme crucial for immune-system function; its absence causes severe combined immunodeficiency (ADA-SCID). The deficiency results from the deletion of the gene for adenosine deaminase, and its consequence is dysfunction of the immune system — the NEET 2021 fact. Two earlier approaches existed for some patients: bone-marrow transplantation (curative only when a matched donor is available) and enzyme replacement (injected ADA), but neither was completely curative. Gene therapy offered a deeper fix. Lymphocytes were drawn from the patient's blood and grown in culture outside the body. A functional ADA cDNA was introduced using a retroviral vector, and the engineered lymphocytes were returned to the patient. Because lymphocytes are not immortal — they die over time — the procedure must be repeated periodically. A permanent cure would require introducing the gene into cells at the early embryonic stage, where it could persist for the patient's life.

Molecular diagnosis — PCR & ELISA

Effective treatment depends on early diagnosis, and early diagnosis depends on detecting pathogens or mutations before symptoms appear. Conventional methods — serum and urine analysis — fail this test. They flag the disease only after the pathogen load is high enough to cause symptoms. Three modern techniques bypass that delay: Polymerase Chain Reaction (PCR), Enzyme-Linked Immuno-Sorbent Assay (ELISA), and recombinant DNA probes with autoradiography. NEET 2023 turned the contrast directly into a question — which technique does NOT serve early diagnosis? The answer was serum and urine analysis.

PCR amplifies even minute amounts of pathogen nucleic acid. A few viral copies — far below the threshold of any antibody-based test — can be detected through repeated cycles of denaturation, annealing, and extension. PCR is routinely used to detect HIV in suspected AIDS patients and HCV, as well as to identify mutations in suspected cancer patients and to diagnose many other genetic disorders.

The probe-and-autoradiography approach uses a single-stranded DNA or RNA labelled with a radioactive molecule. The probe is allowed to hybridise to its complementary DNA in a clone of cells, followed by detection using autoradiography. The clone bearing the mutated gene fails to appear on the photographic film because the probe lacks complementarity with the mutated sequence — a logic that NEET 2021 turned into a direct question about cancer-mutation detection.

ELISA works on a different principle entirely — antigen-antibody interaction. Infection by a pathogen can be confirmed either by detecting the antigens it carries (proteins, glycoproteins) or by detecting antibodies the immune system has produced against it. ELISA is fast, cheap, and well-suited to large-scale screening; PCR is more sensitive at very low concentrations and works on nucleic acid rather than protein.

Transgenic animals

An animal whose DNA has been manipulated to carry and express an extra (foreign) gene is a transgenic animal. Transgenic rats, rabbits, pigs, sheep, cows, and fish have all been produced — but more than 95% of all existing transgenic animals are mice. NCERT lists five categories of reasoning behind their production, and NEET expects you to recall at least three of them in detail.

The first is normal physiology and development: transgenic animals let scientists watch how a gene is regulated and how it shapes the body. The work on the insulin-like growth factor depended on this — introducing genes from other species that altered IGF formation revealed the factor's biological role. The second is study of disease. Transgenic models exist today for cancer, cystic fibrosis, rheumatoid arthritis, and Alzheimer's, allowing investigation of new treatments before human trials are contemplated. The third is the production of biological products. Medicines based on biologicals can be expensive; transgenic animals engineered to secrete those proteins in milk make the supply cheap. The 1997 milestone here was the cow Rosie, the first transgenic cow to produce human protein-enriched milk — 2.4 g per litre of human α-lactalbumin, a more balanced nutrient for human babies than ordinary cow milk. Human α-1-antitrypsin (for emphysema), phenylketonuria therapy, and cystic fibrosis treatment are all targets of similar approaches.

The fourth use is vaccine safety testing: transgenic mice carrying the genes that make them susceptible to particular viruses are being developed to replace monkeys in tests of polio vaccine batches. The fifth is chemical safety / toxicity testing — transgenic animals engineered to be especially sensitive to specific toxins let scientists assess hazards in less time and with fewer animals than conventional protocols.

Ethical issues, GEAC & biopiracy

The manipulation of living organisms cannot proceed without rules. Genetic modification can have unpredictable effects when modified organisms enter ecosystems, and the moral terrain — what humans may and may not do to other species, to ourselves, to the genome — is contested. The Indian Government's response is the Genetic Engineering Appraisal Committee (GEAC) — earlier titled the Genetic Engineering Approval Committee — which assesses the safety of introducing GM organisms for public use and decides on the validity of GM research. NEET 2018 turned this into a direct one-mark question: which Indian body assesses the safety of GMOs for public use? The answer is GEAC, not ICMR, not CSIR, not RCGM.

The harder question is ownership. Patents granted on products and technologies derived from genetic materials, plants, and biological resources long developed by indigenous and traditional communities have provoked widespread anger. Rice has been cultivated in Asia for thousands of years; India alone has an estimated 200,000 varieties. Basmati — distinct in aroma and flavour, with 27 documented varieties grown in India and references in ancient texts — was patented in 1997 by an American company through the US Patent and Trademark Office. The patented "new" variety had actually been derived by crossing Indian farmers' Basmati with semi-dwarf lines and was claimed as an invention. Because patents extend to functional equivalents, the move threatened to restrict other sellers of Basmati rice itself. Similar attempts have targeted turmeric, neem, and other Indian traditional herbal medicines.

Biopiracy is the term for the use of bio-resources by multinational companies and other organisations without proper authorisation from the countries and people concerned, and without compensatory payment. Industrialised nations are financially rich but biologically poor; developing nations are biologically rich and financially poor, with deep traditional knowledge that can be exploited to save decades of R&D in commercial product development. The Indian Parliament has passed the second amendment of the Indian Patents Bill to address these concerns — including patent terms, emergency provisions, and protections for research and development on India's biological inheritance.